Vaccination in patients with primary immunodeficiciencies
Keywords:
Vaccination, Immunodeficiency, Replicative vaccines, Anti-SARS Cov-2 vaccination.Abstract
In immunocompromised patients, correct immunization is essential because they have a higher risk of infection. An observational-descriptive-retrospective research was carried out to describe the vaccination process of patients with primary immunodeficiencies in Granma, between 2012 and 2021, in a sample of 39 cases. The data was collected from medical records and vaccination cards. Absolute and relative frequencies and the SPSS 25 statistical processor were used. BCG was administered to 100% of the patients. In 85% of children under 10 years of age, the PRS vaccine was opportunely contraindicated and the oral anti-polio vaccine was administered to 10 patients. The DT and DPT vaccines were applied to 65 and 95% of the patients, respectively. Five children received anti-pneumococcal vaccine and 94.87% immunoprophylaxis for SARS CoV-2. Common Variable Immunodeficiency and BCG were the PID and the vaccine, respectively, with more difficulty for their correct management.
Downloads
References
1. Bonilla FA. Vaccines in Patients with Primary Immune Deficiency. Immunol Allergy Clin N Am. 2020; 40: 421–35.
2. Tangye SG, Al Herz W, Bousfiha A, Chatila T, Cunningham Rundles C, Etzioni A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020 Jan; 40(1): 24-64.
3. Macías Abraham C, Castro Pacheco BL, González Alemán M, Varcárcel Sánchez M, Noda Albero A, Marsán Suárez V, et al. Inmunización del enfermo inmunocomprometido en Cuba. Consenso de criterios. Rev Cubana Hematol Inmunol Hemoter. 2013; 29(1): 48-58.
4. Milito C, Soccodato V, Collalti G, Lanciarotta A, Bertozzi I, Rattazzi M, et al. Vaccination in PADs. Vaccines (Basel). 2021; 9(6): 626.
5. Condino Neto A, Sorensen RU, Gómez Raccio AC, King A, Espinosa Rosales FJ, Franco JL. Current state and future perspectives of the Latin American Society for Immunodeficiencies (LASID). Allergol Immunopathol. 2015; 43(5): 493-7.
6. Macías C, Marsán V, Sánchez M, Ustariz C, Alfonso M, Adams Y, et al. Registro Cubano de Inmunodeficiencias Primarias. Rev Cubana de Hematol Inmunol Hemoter. [Internet]. 2019 [citado 22/06/2022]; 36(S1): [aprox. 5 p.]. Disponible en: file:///C:/Users/Lucy/Downloads/791-5127-1-PB-1.pdf
7. Wu J, Zhong W, Yin Y, Zhang H. Primary immunodeficiency disease: a retrospective study of 112 Chinese children in a single tertiary care center. BMC Pediatr. 2019; 19(1): 410.
8. Kinoshita H, Durkee Shock J, Jensen Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, et al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. J Clin Immunol. 2021; 41(6): 1146-53.
9. Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino Neto A, et al. Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-Vaccine-Derived Complications: A Systematic Review. J Allergy Clin Immunol Pract. 2020; 8(4): 1371-86.
10. Sarmiento JD, Villada F, Orrego JC, Franco JL, Trujillo Vargas CM. Adverse events following immunization in patients with primary immunodeficiencies. Vaccine. 2016 Mar 18; 34(13): 1611-16.
11. Galindo BM, Concepción D, Galindo MA, Pérez A, Saiz J. Vaccine-related adverse events in Cuban children, 1999-2008. MEDICC Rev. 2012 Jan; 14(1): 38-43.
12. Ho HE, Mathew S, Peluso MJ, Cunningham Rundles C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. J Allergy Clin Immunol Pract. 2021; 9(1): 490-3.
13. Toledo Romaní ME, Verdecia Sánchez L, Rodríguez González M, Rodríguez Noda L, Valenzuela Silva C, Paredes Moreno B, et al. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Vaccine. 2022; 40(31): 4220-30.
14. Hernández Bernal F, Ricardo Cobas MC, Martín Bauta Y, Navarro Rodríguez Z, Piñera Martínez M, Quintana Guerra J, et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). E Clinical Medicine. 2022; 46: 101383.
15. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Front Immunol. 2021; 12: 727850.
Downloads
Published
How to Cite
Issue
Section
License
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
